Soft Tissue Sarcoma Clinical Trials 2024

Soft Tissue Sarcoma Clinical Trials 2024

Soft Tissue Sarcoma research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in soft tissue sarcoma clinical trials today.

Soft Tissue Sarcoma Clinical Trials

Here are the 6 most popular medical studies for soft tissue sarcoma

Popular filter options for soft tissue sarcoma trials

STS Clinical Trials

View 77 STS medical studies.

Rhabdomyosarcoma Clinical Trials

View 76 Rhabdomyosarcoma medical studies.

Metastatic Soft Tissue Sarcoma Clinical Trials

View 95 metastatic soft tissue sarcoma medical studies.

Soft Tissue Sarcoma Clinical Trials With No Placebo

View 95 soft tissue sarcoma medical studies that do not have a placebo group.

View More Soft Tissue Sarcoma Trials

See another 73 medical studies focused on soft tissue sarcoma.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to soft tissue sarcoma

What are the top hospitals conducting soft tissue sarcoma research?

In the realm of soft tissue sarcoma, several top hospitals are actively engaged in groundbreaking clinical trials. At Memorial Sloan Kettering Cancer Center in New york City, researchers are spearheading eight ongoing trials focused on this complex condition. While they may have conducted only two previous studies so far, their commitment to advancing knowledge and treatment is evident since recording their first ever soft tissue sarcoma trial in 2018. In Saint Louis, both Washington University School of Medicine and Washington University play integral roles as well. The former currently hosts six active clinical trials for soft tissue sarcoma with no prior completed investigations to date. Similarly, at the latter institution, five ongoing trials are dedicated to understanding and combating this rare cancer type without any past recorded studies.

Moving southward to Tampa's Moffitt Cancer Center unveils another center that prioritizes research in soft tissue sarcomas. With a considerable number of five active clinical trials underway presently but no historical records available yet, they contribute significantly towards uncovering new insights into these challenging tumors.

Finally making our way back up north again towards Boston's medical landscape we find Dana-Farber Cancer Institute playing a vital role by conducting four current clinical experiments; although unrecorded history can be traced indicating it being void of previously held investigation measures.

These leading hospitals represent not only centers of excellence but also symbols of hope for individuals battling soft tissue sarcomas worldwide. Through pioneering research and patient-centric approaches fostered within these institutions' premises comes the potential for improved outcomes and a brighter future for all those affected by this complex disease

Which are the best cities for soft tissue sarcoma clinical trials?

When it comes to soft tissue sarcoma clinical trials, several cities have emerged as leaders in research and development. New york, Saint Louis, Boston, Los Angeles, and Philadelphia are at the forefront with multiple ongoing studies focused on different treatments like paclitaxel, olaratumab, ramucirumab, pembrolizumab, and more. These cities provide individuals with access to cutting-edge clinical trials that explore various approaches for treating soft tissue sarcoma. With their commitment to advancing medical knowledge and improving patient outcomes, these cities offer promising opportunities for those affected by this condition.

Which are the top treatments for soft tissue sarcoma being explored in clinical trials?

Soft tissue sarcoma research is making significant strides in clinical trials, with a number of promising treatments at the forefront. Among these top contenders are:

  • Pazopanib: Demonstrating potential in soft tissue sarcoma, pazopanib is currently being explored in multiple ongoing clinical trials.
  • Trabectedin: Also showing promise, trabectedin has garnered attention in several active trials focused on soft tissue sarcoma.
  • Olaratumab: Another treatment under investigation for its efficacy against soft tissue sarcoma, olaratumab is actively being studied to determine its effectiveness. These innovative therapies hold immense hope for patients battling this challenging cancer type as researchers continue to uncover new avenues for treatment.
What are the most recent clinical trials for soft tissue sarcoma?

Recent clinical trials for soft tissue sarcoma offer promising avenues for treatment and improved outcomes. One notable study involves the use of lurbinectedin, ipilimumab, and nivolumab in advanced soft tissue sarcoma patients. This combination therapy shows potential in effectively combating this challenging disease. Another trial focuses on dose selection to optimize treatment efficacy. Furthermore, a single-arm open-label study explores alternative approaches that may benefit patients with soft tissue sarcomas. Additionally, the investigation into niraparib as a therapeutic option demonstrates encouraging results. Lastly, intensity-modulated radiation therapy (IMRT) is being evaluated as an effective treatment modality for soft tissue sarcoma patients seeking better therapeutic options. These diverse studies represent significant advancements in the quest to improve outcomes for individuals battling soft tissue sarcomas

What soft tissue sarcoma clinical trials were recently completed?

Recently completed clinical trials have made significant strides in the field of soft tissue sarcoma research. These trials focused on investigating novel treatments to combat this challenging cancer. A notable trial sponsored by Memorial Sloan Kettering Cancer Center was concluded, bringing us closer to understanding the potential benefits of targeted therapies for soft tissue sarcoma patients. By harnessing the power of precision medicine, researchers are working tirelessly to improve outcomes and offer hope to individuals affected by this complex disease.